Related Experiment Video
Updated: Jan 2, 2026
Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
Published on: October 10, 2025
Recent progress in mapping the emerging landscape of the small-cell lung cancer genome
Kee-Beom Kim1, Colin T Dunn2, Kwon-Sik Park3
1Departments of Microbiology, Immunology, and Cancer Biology, University of Virginia School of Medicine, Charlottesville, VA, 22908, USA.
Abstract:
Small-cell lung cancer (SCLC) remains the deadliest of all the lung cancer types. Its high mortality is largely attributed to the invariable development of resistance to standard chemo/radiotherapies, which have remained unchanged for the past 30 years, underscoring the need for new therapeutic approaches. The discovery of molecular targets for chemoprevention and treatment has been hampered by the poor understanding of SCLC progression. In recent years, comprehensive omics-based analyses have led to the discovery of recurrent alterations in patient tumors, and functional studies using genetically engineered mouse models and patient-derived tumor models have provided information about the alterations critical for SCLC pathogenesis. Defining the somatic alterations scattered throughout the SCLC genome will help to understand the underlying mechanism of this devastating disease and pave the way for the discovery of therapeutic vulnerabilities associated with the genomic alterations.
Insights
Small-cell lung cancer (SCLC) is deadly due to treatment resistance. Understanding its genomic alterations is key to finding new therapies for this aggressive disease.
Area of Science:
- Oncology
- Genomics
- Molecular Biology
Background:
- Small-cell lung cancer (SCLC) exhibits high mortality, largely due to acquired resistance to current chemo/radiotherapies.
- Existing SCLC treatments have seen little advancement in 30 years, highlighting an urgent need for novel therapeutic strategies.
- A limited understanding of SCLC progression impedes the identification of effective molecular targets for treatment and prevention.
Purpose of the Study:
- To explore the genomic landscape of SCLC through comprehensive omics-based analyses.
- To identify critical genetic alterations driving SCLC pathogenesis using functional studies.
- To define somatic alterations in the SCLC genome to uncover underlying disease mechanisms and therapeutic vulnerabilities.
Main Methods:
- Utilizing comprehensive omics-based analyses on patient tumors.
- Conducting functional studies with genetically engineered mouse models.
- Employing patient-derived tumor models for in-depth investigation.
Main Results:
- Recurrent genetic alterations have been identified in SCLC patient tumors.
- Functional studies have elucidated critical alterations involved in SCLC pathogenesis.
- Genomic alterations provide insights into the molecular mechanisms of SCLC.
Conclusions:
- Defining somatic alterations across the SCLC genome is crucial for understanding disease mechanisms.
- Identifying genomic alterations will facilitate the discovery of new therapeutic vulnerabilities.
- This research paves the way for developing novel treatment strategies for SCLC.
